Rett syndrome is a rare genetic neurodevelopmental disorder that disrupts brain development and leads to progressive loss of motor and language skills after an early period of apparently typical development. It primarily affects females and is associated with severe long-term neurological impairment.
The FDA has denied or discouraged at least eight drug applications in the past year, including treatments for rare diseases, raising concerns about regulatory consistency and the future of experimental therapies.
The FDA granted Breakthrough Therapy designation to NGN-401, Neurogene's gene therapy for Rett syndrome, based on interim data showing durable functional improvements. The company expects to complete pivotal trial dosing in Q2 2026.
Artificial intelligence is revolutionizing rare disease diagnosis, cutting diagnostic timelines from years to weeks. Rare Disease Day on February 28 highlights challenges faced by over 300 million people worldwide living with more than 7,000 distinct rare conditions.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07569445 |
Auditory EEG and Behavioral Assessments in Individuals With Rett Syndrome |
RECRUITING | |
| NCT07503444 |
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome |
NOT_YET_RECRUITING | PHASE3 |
| NCT07480564 |
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome |
RECRUITING | PHASE3 |
| NCT07418905 |
Technology-supported Motor Rehabilitation for People With Rett Syndrome |
ACTIVE_NOT_RECRUITING | NA |
| NCT07257978 |
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07151950 |
Obi Medical Robot: Evaluating Effectiveness Related to Usability |
ACTIVE_NOT_RECRUITING | |
| NCT07150013 |
Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome |
RECRUITING | PHASE1 |
| NCT06856759 |
Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome |
RECRUITING | EARLY_PHASE1 |
| NCT06849973 |
To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome |
COMPLETED | PHASE2/PHASE3 |
| NCT06840496 |
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome |
RECRUITING | PHASE3 |
